$3.10
-0.05 (-1.59%)
Open$3.16
Previous Close$3.15
Day High$3.29
Day Low$3.10
52W High$13.13
52W Low$2.13
Volume—
Avg Volume33.28M
Market Cap45.25M
P/E Ratio—
EPS$-3.27
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,063.9% upside
Current
$3.10
$3.10
Target
$36.08
$36.08
$23.71
$36.08 avg
$52.26
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.74M | 8.74M | 8.70M |
| Net Income | -38,664,594 | -76,794 | -87,592 |
| Profit Margin | -673.1% | -0.9% | -1.0% |
| EBITDA | -40,570,339 | -105,264 | -93,337 |
| Free Cash Flow | — | -51,137 | -57,721 |
| Rev Growth | — | +8.7% | -7.3% |
| Debt/Equity | — | 0.73 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |